A5023015071- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Cancer Treatment and Pharmacology
- Signaling Pathways in Disease
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- T-cell and B-cell Immunology
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Immunotherapy and Immune Responses
- Colorectal Cancer Surgical Treatments
Bayreuth Medical Center
2015-2024
Comprehensive Cancer Center Erlangen
2021-2024
University Hospital Carl Gustav Carus
2004-2020
Heidelberg University
2015
University Hospital Heidelberg
2015
TU Dresden
2000-2010
Klinik und Poliklinik für Psychotherapie und Psychosomatik
2005-2009
Städtisches Klinikum Dresden
2009
University of Tehran
2006
Harvard University
1997-2001
This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis CD34+ blood cells to pre-empt relapse in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). At median 169 days HSCT, 20/59 prospectively screened experienced decrease <80% and received four cycles (75 mg/m2/day for 7 days) while complete hematologic remission. A total 16...
Steroid refractory chronic graft-versus-host disease (cGVHD) is associated with a significant morbidity and mortality. Although first-line treatment of cGVHD based on controlled trials, second-line almost solely phase II trials or retrospective analyses. The consensus conference clinical practice in held Regensburg aimed to achieve the current evidence options as well provide guidelines for daily practice. Treatment modalities are use steroids calcineurin inhibitors immunomodulating...
BackgroundFIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to their gene-signature four different subtypes. Relevance of CMS for the treatment mCRC has yet be defined.Patients and MethodsIn this exploratory analysis, patients were grouped previously published tumor CRC-CMSs. Objective response rates (ORR)...
Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation is still associated with significant morbidity and mortality. First-line treatment of cGVHD based on steroids 1 mg/kg/day prednisone. The role calcineurin inhibitors remains controversial, especially in patients low risk for mortality (normal platelets counts), whereas at diagnosis and/or high steroid toxicity may be treated upfront the combination prednisone a inhibitor. Additional systemic...
Purpose We investigated choice and efficacy of subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus cetuximab [arm A] or bevacizumab B]) for patients KRAS wild-type metastatic colorectal cancer. Patients Methods Start subsequent-line (second third) therapy was defined as use an antitumor drug that not part previous regimen. evaluated choice, duration, determined impact treatment outcome FIRE-3. Results Of 592 intent-to-treat population, 414...
Abstract Background Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab in KRAS wild-type metastatic colorectal cancer (mCRC) FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis aimed to determine whether cetuximab improves response and versus among response-evaluable patients receiving first-line RAS mCRC the effect of primary tumour side on outcomes. Methods The intent-to-treat population included 593 exon 2 mCRC. Further...
445 Background: The FIRE-3 study (AIO KRK-0306) was designed as a randomized multicenter trial to compare the efficacy of FOLFIRI plus cetuximab (cet) bevacizumab (bev) first-line treatment in KRAS WT mCRC patients. cet patients resulted comparable overall response rates (ORR) and progression free survival (PFS) when compared bev. Overall (OS) significantly longer arm. Methods: In preplanned analysis, effect mutations within EGFR dependent pathway were investigated. Next (exon 2, 3, 4), NRAS...
LBA3506 The full, final text of this abstract will be available at abstract.asco.org 7:30 AM (EDT) on Saturday June, 1, 2013, and in the Annual Meeting Proceedings online supplement to June 20, issue Journal Clinical Oncology. Onsite Meeting, printed edition ASCO Daily News.
Abstract Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition imminent blastic proliferation and a timelier change treatment unknown. One thousand five hundred ten imatinib-treated patients with Philadelphia-chromosome-positive (Ph+) CML randomized CML-study IV were analyzed for ACA/Ph+ blast increase. By impact on survival, ACAs grouped into high risk (+8, +Ph, i(17q), +17, +19,...
Abstract Early results of the randomized placebo-controlled SORAML trial showed that, in patients with newly diagnosed acute myeloid leukaemia (AML), sorafenib led to a significant improvement event-free (EFS) and relapse-free survival (RFS). In order describe second-line treatments their implications on overall (OS), we performed study after median follow-up time 78 months. Newly fit AML aged ≤60 years received ( n = 134) or placebo 133) addition standard chemotherapy as maintenance...
Guidelines recommend a structured symptom screening (SC) for especially advanced cancer patients (CPs). The aim of this multicenter German prospective quality assurance project KeSBa (Kennzahl Symptom- und Belastungserfassung) was to gain knowledge on SC procedures in Oncology Centers (OCs) and first impression the consequences SC.
Abstract Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity condition and heterogeneity biology presentation, prospective trials concise treatment recommendations are lacking. Here we present analysis European LeukemiaNet Phase Registry, international collection outcome blast phases which had been diagnosed in CML patients after 2015. Data reveal expected entity, lacking clear standard. Outcomes remain dismal,...
3600 Background: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type mCRC patients. We analyzed the efficacy dependent on gender and primary tumor location within RAS population (n=342). Methods: Primary was defined as follows: right sided CRC (RCRC): coecum to hepatic flexure; left (LCRC): splenic flexure rectum. Colon transversum tumors (n=9) were excluded. Differences response (ORR) survival (PFS/OS) both treatment arms...